|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 860 WINTER STREET |
Address2 |
|
| City | WALTHAM |
State | MA |
Zip Code | 02451 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 23975-12
|
||||||||
|
6. House ID# 319670000
|
||||||||
| TYPE OF REPORT | 8. Year | 2017 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Lois Dehls Cornell, Executive Vice President |
Date | 1/18/2018 1:27:16 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Legislation to Repeal/Revise the Affordable Care Act
Efforts to repeal and/or revise the Patient Protection and Affordable Care Act including funding of Cost Sharing Reduction Subsidies, changes to Medicaid, essential benefits requirements and elimination of the individual mandate.
Alexander-Murray Bill on Cost-Sharing Reduction Funding and Section 1332 Waivers
HR 1 Tax Cuts and Jobs Bill - PL 115-97
Elimination of the Individual mandate under the ACA
Cuts to Medicare, Medicaid, domestic and Health Care Programs
Impact on Medical Student loans
HR 3770, S. 1899 - Community Health Investment, Modernization, and Excellence Act of 2017 - Community Health Centers Reauthorization
S. 1827 Keep Kids Insurance Dependable and Secure - CHIP reauthorization
HR 3922 Championing Healthy Kids Act - CHIP reauthorization
Increased funding and focus on the social determinants of health, including food - No specific bill
MACRA - Revisions to the Medicare Access and Chip Reauthorization Act - no specific bill
Prescription Drug Prices
S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions.
Efforts to address the cost of prescription drugs, including proposals to include the manufacturers suggested retail price in direct to consumer advertising of prescription drugs - no specific bill
Opioids
Comprehensive Addiction and Recovery Act - Funding for opioid abuse prevention and treatment programs - no specific bill
HR 1372 - Prescriber Support Act - Grants to states for programs to help prescribers (1) treat and manage patient pain; and (2) prevent, identify, and respond to patient substance misuse and substance abuse disorder
ERX of Schedule II drugs - Efforts to make eprescribing of Schedule II drugs more feasible - no specific bill
Safe Injection Facilities - no specific bill
S. 1554 Safer Prescribing of Controlled Substances Act - Federal Mandates for Opioid Prescriber Education
Federal Student Loan forgiveness for substance abuse prevention and treatment professionals - no specific bill
Increased funding for SAMHSAs Community Mental Health Services Block Grant (MHBG) and funding for SAMHSAs Programs of Regional and National Significance
Gun Violence
HR 1832, S.834 - A bill to authorize the appropriation of funds to the Centers for Disease Control and Prevention for conducting or supporting research on firearms safety or gun violence prevention.
Telemedicine
S. 870 - Creating High Quality Results and Outcomes Necessary to Improve Chronic Care
HR 2556 - Connect for Health Act of 2017
HR 849 - Protecting Seniors' Access to Medicare Act of 2017 - Efforts to repeal IPAB
Regulatory Issues
CMS - Removal of Social Security Numbers from Medicare Cards
Electronic medical records - efforts to streamline and improve interoperability - no specific bill
DEA issues
Updated regulations to implement Partial Fill law
Updated regulations for Eprescribing of Controlled Substances.
Executive Order creating Association Health Plans
MedPac recommendations re MIPS
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Legislation to Repeal/Revise the Affordable Care Act
Efforts to repeal and/or revise the Patient Protection and Affordable Care Act including funding of Cost Sharing Reduction Subsidies, changes to Medicaid, essential benefits requirements and elimination of the individual mandate.
Alexander-Murray Bill on Cost-Sharing Reduction Funding and Section 1332 Waivers
HR 1 Tax Cuts and Jobs Bill - PL 115-97
Elimination of the Individual mandate in the ACA
Cuts to Medicare, Medicaid, domestic and Health Care Programs
Impact on Medical Student loans
HR 3770, S. 1899 - Community Health Investment, Modernization, and Excellence Act of 2017 - Community Health Centers Reauthorization
S. 1827 Keep Kids Insurance Dependable and Secure - SCHIP reauthorization
Increased funding and focus on the social determinants of health, including food - No specific bill
MACRA - Revisions to the Medicare Access and Chip Reauthorization Act - no specific bill
Prescription Drug Prices
S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions.
Efforts to address the cost of prescription drugs, including proposals to include the manufacturers suggested retail price in direct to consumer advertising of prescription drugs - no specific bill
Opioids
Comprehensive Addiction and Recovery Act - Funding for opioid abuse prevention and treatment programs - no specific bill
HR 1372 - Prescriber Support Act - Grants to states for programs to help prescribers (1) treat and manage patient pain; and (2) prevent, identify, and respond to patient substance misuse and substance abuse disorder
ERX of Schedule II drugs - Efforts to make eprescribing of Schedule II drugs more feasible - no specific bill
Safe Injection Facilities - no specific bill
S. 1554 Safer Prescribing of Controlled Substances Act - Federal Mandates for Opioid Prescriber Education
Federal Student Loan forgiveness for substance abuse prevention and treatment professionals - no specific bill
Increased funding for SAMHSAs Community Mental Health Services Block Grant (MHBG) and funding for SAMHSAs Programs of Regional and National Significance
Gun Violence
HR 1832, S.834 - A bill to authorize the appropriation of funds to the Centers for Disease Control and Prevention for conducting or supporting research on firearms safety or gun violence prevention.
Telemedicine
S. 870 - Creating High Quality Results and Outcomes Necessary to Improve Chronic Care
HR 2556 - Connect for Health Act of 2017
HR 849 - Protecting Seniors' Access to Medicare Act of 2017 - Efforts to repeal IPAB
Electronic medical records - efforts to streamline EMRs, improve interoperability - no specific bill
DEA related issues
Updated regulations to implement Partial Fill law
Updated regulations for Eprescribing of Controlled Substances.
MedPac recommendations re MIPS
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
Comprehensive Addiction and Recovery Act - Funding for opioid abuse prevention and treatment programs - no specific bill
HR 1372 - Prescriber Support Act - Grants to states for programs to help prescribers (1) treat and manage patient pain; and (2) prevent, identify, and respond to patient substance misuse and substance abuse disorder
ERX of Schedule II drugs - Efforts to make eprescribing of Schedule II drugs more feasible - no specific bill.
Safe Injection Facilities - no specific bill
S. 1554 Safer Prescribing of Controlled Substances Act - Federal Mandates for Opioid Prescriber Education
Federal Student Loan forgiveness for substance abuse prevention and treatment professionals - no specific bill
Increased funding for SAMHSAs Community Mental Health Services Block Grant (MHBG) and funding for SAMHSAs Programs of Regional and National Significance
DEA related issues
Updated regulations to implement Partial Fill law
Updated regulations for Eprescribing of Controlled Substances.
Executive Order creating Association Health Plans
MedPac recommendations re MIPS
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions.
Efforts to require the manufacturers suggested retail price of prescription drugs in direct to consumer advertising of prescription drugs - no specific bill
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FIR
16. Specific lobbying issues
Gun Violence
HR 1832, S.834 - A bill to authorize the appropriation of funds to the Centers for Disease Control and Prevention for conducting or supporting research on firearms safety or gun violence prevention.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
HR 496, S. 128 - Bridge Act - Codifies DACA protections for three years.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |